Note 2 - Summary of Significant Accounting Policies (Details Textual) $ / shares in Units, $ in Thousands |
3 Months Ended | ||
|---|---|---|---|
|
Jan. 31, 2022
$ / shares
|
Apr. 30, 2022
USD ($)
|
Oct. 31, 2021
USD ($)
|
|
| Accounts Receivable, Allowance for Credit Loss, Ending Balance | $ 700 | $ 700 | |
| Inventory Valuation Reserves, Ending Balance | $ 0 | $ 0 | |
| Supplier Concentration Risk [Member] | Cost of Goods and Service Benchmark [Member] | |||
| Number of Vendors | 3 | 3 | |
| Time Based Only [Member] | |||
| Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares | $ 1 |
| X | ||||||||||
- Definition Represents number of significant vendors. No definition available.
|
| X | ||||||||||
- Definition Amount of allowance for credit loss on accounts receivable. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of valuation reserve for inventory. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|